Transplant Trial Watch

The effect of mannitol on oxidation-reduction potential in patients undergoing deceased donor renal transplantation - A randomized controlled trial.

Reiterer, C., et al.

Acta Anaesthesiol Scand 2020 [record in progress].


Aims
This study aimed to investigate whether mannitol was effective in reducing overall oxidative stress in recipients of deceased donor kidney transplants.

Interventions
Patients were randomly assigned to either the mannitol group or the placebo group.

Participants
34 patients undergoing deceased donor kidney transplantation.

Outcomes
The primary endpoints were the effect of mannitol on overall static oxidative-reduction potential (sORP) and capacity of the oxidative-reduction potential (cORP). The secondary endpoint was the assessment of percentage change of sORP and cORP values from baseline.

Follow-up
N/A

CET Conclusions
This is a small but well conducted double-blinded RCT in renal transplantation. 34 transplant recipients were randomised to receive a placebo infusion or 1g/Kg infusion of mannitol prior to graft reperfusion. The study size was predicated on results in partial liver resection. Serum markers for oxidative stress were measured using the RedoxSYS Diagnostic System (Aytu Bioscience Inc), which were expressed as Static Oxidative Reduction Potential and Capacity of Oxidative Reduction Potential. There was no significant difference in either of these parameters comparing mannitol to placebo. Unfortunately, the study was not powered to detect clinically relevant outcomes and they are not reported beyond the intra-operative parameters.

Jadad score
5

Data analysis
Per protocol analysis

Allocation concealment
Yes

Trial registration
ClinicalTrials.gov - NCT02705573

Funding source
Not reported